[User Manual] KILR® CD16 Effector Cells
- Year:
- 2022
KILR CD16 Effector Cells are purified human cytotoxic T lymphocytes stably expressing CD16 (FcγRIIIa; V158 variant), produced in a standardized batch. The cells were developed for Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and T Cell Redirection (TCR) applications to reproducibly mediate target cell death.
The KILR cytotoxicity target cell line enables the development of a simple, non-radioactive and dye-free method to specifically measure target cell death in a co-culture. The KILR assay has several applications in Cancer Immunotherapy (iOnc) drug development including measuring target cell death through ADCC, Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell Phagocytosis (ADCP), Cytotoxic T Cell Lymphocyte-Mediated Death (CTL), Bi-specific Antibody Mediated T Cell Redirection, Chimeric Antigen Receptor T Cell (CAR-T), and adoptive T cell therapies. This assay can drive all aspects of the drug discovery process, from screening to characterization, and the development of a QC lotrelease assay for the immunotherapy drugs.